[{"Assets_0_Q2_USD":2321300000.0,"CommonStockSharesOutstanding_0_Q2_shares":51600000.0,"NetCashProvidedByUsedInOperatingActivities_2_Q2_USD":69000000.0,"NetIncomeLoss_1_Q2_USD":-9500000.0,"NetIncomeLoss_2_Q2_USD":-35600000.0,"WeightedAverageNumberOfSharesOutstandingBasic_1_Q2_shares":51500000.0,"WeightedAverageNumberOfSharesOutstandingBasic_2_Q2_shares":51300000.0,"StockholdersEquity_0_Q2_USD":988900000.0,"EarningsPerShareBasic_1_Q2_USD":-0.18,"EarningsPerShareBasic_2_Q2_USD":-0.69,"Ticker":"EBS","CIK":"1367644","name":"EMERGENT BIOSOLUTIONS INC.","OfficialName":"Emergent Biosolutions Inc. Common Stock","form":"10-Q","period":"20190630","fy":"2019.0","fp":"Q2","qtrs":"0","uom":"USD","footnote":"nan","Market Cap":"2077670312.0","Country":"United States","Sector":"Health Care","Industry":"Biotechnology: Pharmaceutical Preparations","Market":"NYSE","SP500":"nan","filed":"20190802"}]